Compounds > chlorpromazine n-oxide
Page last updated: 2024-12-08

chlorpromazine n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chlorpromazine N-oxide : An organochlorine compound that is chlorpromazine in which the acyclic tertiary amino group has been converted into the corresponding N-oxide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID443037
CHEMBL ID3220941
CHEBI ID3648
SCHEMBL ID2856438
MeSH IDM0133839

Synonyms (21)

Synonym
[3-(2-chloro-10h-phenothiazin-10-yl)propyl]dimethylamine oxide
CHEBI:3648 ,
2-chloro-10-(3'-dimethyloxidoaminopropyl)phenothiazine
PDSP1_001498
PDSP2_001482
chlorpromazine n-oxide
1672-76-0
3-(2-chlorophenothiazin-10-yl)-n,n-dimethylpropan-1-amine oxide
ba 2836
10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, n-oxide
chlorpromazine oxide
nsc_443037
bdbm82476
chlorpromazine-n-oxide
cas_443037
CHEMBL3220941
SCHEMBL2856438
3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethylpropan-1-amine n-oxide
DTXSID90937295
Q27106158
3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethylpropan-1-amine oxide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The discrepancies observed were not only due to nonspecificity of the immunoassay procedures employed, but also to a lack of rigorous specificity of the HPLC procedure in plasma samples from dosed humans."( Therapeutic monitoring of chlorpromazine. IV: Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites.
Chakraborty, BS; Cooper, JK; Gurnsey, T; Hawes, EM; Hubbard, JW; McKay, G; Midha, KK; Yeung, PK, 1987)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
phenothiazines
tertiary amine oxideAn N-oxide where there are three organic groups bonded to the nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1182150Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of spectinomycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182148Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of 25-desacetylrifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182135Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of spectinomycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182149Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of kanamycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182133Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of 25-desacetylrifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182134Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of kanamycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182146Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of rifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182132Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of rifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182131Antitubercular activity against Mycobacterium smegmatis by checkerboard assay2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (58.33)18.7374
1990's3 (25.00)18.2507
2000's0 (0.00)29.6817
2010's1 (8.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.01 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		4.94120organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		3.1910kanamycinsbacterial metabolite
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		3.1910cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
7-hydroxychlorpromazine
7-hydroxychlorpromazine: RN given refers to parent cpd		440phenothiazines
norchlorpromazine
norchlorpromazine: active metabolite of chlorpromazine; RN given refers to parent cpd		3.5120phenothiazines
opromazine
opromazine: RN given refers to parent cpd; structure in 9th ed, Merck Index, #6697		4.3360phenothiazines
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.1910cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		03.0110
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		03.0110
Dementia Praecox
[description not available]		01.9710
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		01.9710